More pieces to the iron chelation puzzle.
More pieces to the iron chelation puzzle.
复制标题
铁螯合拼图的更多部分。
DOI：
10.1016/j.trsl.2010.06.006
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Waalen,Jill
中科院分区：
文献类型：
--
作者：
Waalen,Jill
定期输血是严重贫血患者的救命治疗，包括β地中海贫血、镰状细胞病、骨髓增生异常综合征和其他疾病。但是，这种治疗是一把双刃剑，每单位输血含有200毫克铁，由于身体没有机制排出多余的铁，慢性铁超载往往导致肝，心脏，内分泌器官和其他组织的损害。因此，铁螯合治疗，发挥了至关重要的作用，在这些患者的管理，因为介绍了肠道外给予螯合剂去铁胺（DFO）超过40年前，在这个问题上，埃文斯等报道在体外动力学研究的DFO与去铁酮（DFP）的相互作用，从地中海贫血患者的血浆中去除非转铁蛋白结合铁。DFP是20世纪80年代末首次用于人类的口服药物，自那时以来，DFO/DFP联合治疗在二十年的大部分时间里一直处于临床研究中。然而，关于这些药物在去除铁方面如何相互作用以及如何最有效地一起施用仍然存在争议。
Regular blood transfusions are life-saving treatment for patients with severe anemias, including those with beta thalassemia, sickle cell disease, myelodysplastic syndromes, and other conditions. But, the treatment is a double-edged sword–each unit of transfused blood contains 200 mg of iron and because the body has no mechanism to excrete excess iron, chronic iron overload often results, causing damage to the liver, heart, endocrine organs, and other tissues. Iron chelation therapy, thus, has played a vital role in the management of these patients since the introduction of the parenterally administered chelator deferoxamine (DFO) more than 40 years ago.In this issue, Evans, et al. report on in vitro kinetic studies of the interaction of DFO with deferiprone (DFP), in removing non-transferrin bound iron from plasma of thalassemic patients. DFP is an oral agent first used in humans in the late 1980s and DFO/DFP combination therapy has been under clinical study for most of the two decades since. However, controversy still exists over how the agents interact in removing iron and how they can be administered together most effectively.